Anthony Scholer

Dr. Anthony Scholer

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in Cancer Epidemiology
Verified
Journal Article
Closed access
ASAnthony Scholer
Anthony Scholer
OMOmar M. Mahmoud
Omar M. Mahmoud
DGDebopyria Ghosh
Debopyria Ghosh
JSJacob Schwartzman
Jacob Schwartzman
MFMohammed Farooq
Mohammed Farooq
RCRavi J. Chokshi
Ravi J. Chokshi

6 July 2020 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
ASAnthony Scholer
Anthony Scholer
AUAbhineet Uppal
Abhineet Uppal
SCShu‐Ching Chang
Shu‐Ching Chang
DGDebopriya Ghosh
Debopriya Ghosh
MKMary Garland‐ Kledzik
Mary Garland‐ Kledzik
MGMelanie Goldfarb
Melanie Goldfarb

2 November 2022 in Journal of Surgical Oncology
Verified
Journal Article
Open access
ASAnthony Scholer
Anthony Scholer
RMRebecca Marcus
Rebecca Marcus
MGMary Garland‐Kledzik
Mary Garland‐Kledzik
SCShu‐Chin Chang
Shu‐Chin Chang
AKAdam Khader
Adam Khader
MGMelanie Goldfarb
Melanie Goldfarb
Background and Objectives: Selecting frail elderly patients with pancreatic cancer (PC) for pancreas resection using biologic age has not been elucidated. This study determined the feasibility of the deficit accumulation frailty index (DAFI) in identifying such patients and its association with surgical outcomes.Methods: The DAFI, which assesses frailty based on biologic age, was used to identify frail patients using clinical and health‐related quality‐of‐life data. The characteristics of frail and nonfrail patients were compared.Results: Of 242 patients (median age, 75.5 years), 61.2% were frail and 32.6% had undergone pancreas resection (surgery group). Median overall survival (mOS) decreased in frail patients (7.13 months, 95% confidence interval [CI]: 5.65–10.1) compared with nonfrail patients (16.1 months, 95% CI: 11.47–34.40, p = 0.001). In the surgery group, mOS improved in the nonfrail patients (49.4%; 49.2 months, 95% CI: 29.3–79.9) compared with frail patients (50.6%, 22.1 months, 95% CI: 18.3–52.4, p = 0.10). In the no‐surgery group, mOS was better in nonfrail patients (54%; 10.81 months, CI 7.85–16.03) compared with frail patients (66%; 5.45 months, 95% CI: 4.34–7.03, p = 0.02).Conclusions: The DAFI identified elderly patients with PC at risk of poor outcomes and can identify patients who can tolerate more aggressive treatments.

17 November 2024 in Journal of Surgical Oncology
Verified
Journal Article
Open access
KLKristel Adeline Lourdault
Kristel Adeline Lourdault
ACArthur W. Cowman
Arthur W. Cowman
DHDouglas Hanes
Douglas Hanes
ASAnthony Scholer
Anthony Scholer
TATyler Aguilar
Tyler Aguilar
RERichard Essner
Richard Essner
Background and Objectives: Clinical nomograms have been developed to predict sentinel lymph node (SLN) status in early‐stage melanoma patients, but the clinical utility of these tools remains debatable. We created and validated a nomogram using data from a randomized clinical trial and assessed its accuracy against the well‐validated Melanoma Institute Australia (MIA) nomogram. Methods: We developed our model to predict SLN status using logistic regression on clinicopathological patient data from the Multicenter Selective Lymphadenectomy Trial‐I. The model was externally validated using the National Cancer Database (NCDB) data set, and its performance was compared to that of the MIA nomogram. Results: Our model had good discrimination between positive and negative SLNs, with a training set area under the curve (AUC) of 0.706 (0.661–0.751). Our model achieved an AUC of 0.715 (0.706–0.724) compared to 0.723 (0.715–0.731) with the MIA model, using the NCDB set. Conclusion: Our model performed similarly to the MIA model, confirming that despite using different clinical features and data sets, no clinical nomogram is currently accurate enough for clinical use.

1 January 2018 in Journal of Surgical Research
Verified
Journal Article
Closed access
ASAnthony Scholer
Anthony Scholer
JOJoseph B. Oliver
Joseph B. Oliver
JRJesus Rosado
Jesus Rosado
JPJimmy S. Patel
Jimmy S. Patel
LLLindsay J. Lynch
Lindsay J. Lynch
RCRavi J. Chokshi
Ravi J. Chokshi

20 March 2023 in Journal of Surgical Oncology
Verified
Journal Article
Open access
JSJuan A. Santamaria‐Barria
Juan A. Santamaria‐Barria
CMChikako Matsuba
Chikako Matsuba
AKAdam Khader
Adam Khader
ASAnthony Scholer
Anthony Scholer
MGMary Garland‐Kledzik
Mary Garland‐Kledzik
MGMelanie Goldfarb
Melanie Goldfarb
Background and Objectives: Melanoma mutational burden is high and approximately 50% have oncogenic mutations inBRAF. We sought to evaluate age‐related mutational differences in melanoma.Methods: We analyzed melanoma samples in the Genomics Evidence Neoplasia Information Exchange database. Targetable mutations were identified using the Precision Oncology Knowledge Base (OncoKB).Results: We found 1194 patients with a common set of 30 genes. The top mutated genes in patients <40 years old (y/o) (n = 98) wereBRAF(59%),TP53(31%),NRAS(17%), andPTEN(14%); in 40–59 y/o (n = 354) wereBRAF(51%),NRAS(30%),TP53(26%), andAPC(13%); and in ≥60 y/o (n = 742) wereBRAF(38%),NRAS(33%),TP53(26%), andKDR(19%).BRAFmutations were almost mutually exclusive fromNRASmutations in <40 y/o (58/59). Mutational burden increased with age, with means of 2.39, 2.92, and 3.67 mutations per sample in patients <40, 40–59, and ≥60 y/o, respectively (p < 0.0001). There were 10 targetable mutations meeting OncoKB criteria for melanoma:BRAF(level 1),RET(level 1),KIT(level 2),NRAS(level 3A),TP53(level 3A), andFGFR2,MET,PTEN,PIK3CA, andKRAS(level 4).Conclusions: Mutations in melanoma have age‐related differences and demonstrates potential targetable mutations for personalized therapies.